Average Co-Inventor Count = 7.99
ph-index = 4
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Deutsches Krebsforschungszentrum (7 from 155 patents)
2. Ruprecht-Karls-Universitat Heidelberg (4 from 63 patents)
3. Ruprecht-Karls-Universitaet Heidelberg (3 from 23 patents)
4. Novartis Ag (2 from 3,923 patents)
5. Ruprecht-Karls-Universität (7 patents)
9 patents:
1. 12054458 - F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer
2. 11951190 - Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer
3. 11931430 - Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
4. 11638765 - Double-labeled probe for molecular imaging and use thereof
5. 11045564 - Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
6. 10815200 - 18F—tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer
7. 10471160 - Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
8. 10398791 - Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
9. 10016519 - 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer